KHK Inhibitor Heterocyclic Compounds Patent Application

The USPTO published a patent application for ketohexokinase (KHK) inhibitor heterocyclic compounds. KHK is an enzyme involved in fructose metabolism and represents a therapeutic target for metabolic disorders. The application discloses compounds of a defined structural formula with pharmaceutical utility, classified across multiple heterocyclic compound categories including C07D 409/14, C07D 413/14, and C07D 495/04, among others. The application claims priority from filing date August 22, 2025, under application number 19307911.

Patent application publications are informational filings that do not create immediate compliance obligations for pharmaceutical manufacturers. No action is required from industry at this stage. The application remains pending and may undergo examination, amendment, or abandonment. If granted in the future, it would provide exclusivity rights to the applicants for the claimed compound structures and methods of use. Manufacturers developing KHK inhibitors should monitor the prosecution of this application and conduct freedom-to-operate analyses before commercializing similar compounds.